Investidor Profissional Gestao de Recursos Ltda. Acquires Shares of 1,188 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Investidor Profissional Gestao de Recursos Ltda. acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,188 shares of the company’s stock, valued at approximately $491,000. IDEXX Laboratories comprises 0.3% of Investidor Profissional Gestao de Recursos Ltda.’s holdings, making the stock its 14th largest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $412,258,000. Flossbach Von Storch SE grew its holdings in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after purchasing an additional 464,791 shares in the last quarter. William Blair Investment Management LLC increased its position in IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after purchasing an additional 369,471 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Finally, Seilern Investment Management Ltd bought a new position in IDEXX Laboratories during the fourth quarter valued at $113,104,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $393.73 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $393.50 and a fifty-two week high of $548.88. The company has a market cap of $31.91 billion, a PE ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The business has a 50-day simple moving average of $435.55 and a two-hundred day simple moving average of $440.31.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.